These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. WHO experience in the therapeutic control of leprosy. Bechelli LM Int J Lepr Other Mycobact Dis; 1971; 39(4):885-9. PubMed ID: 5170476 [No Abstract] [Full Text] [Related]
3. Problems of leprosy relapse in China. Li HY Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):1-7. PubMed ID: 8326169 [TBL] [Abstract][Full Text] [Related]
5. Thirty years of leprosy control work--what next? Dharmendra Lepr India; 1980 Oct; 52(4):566-72. PubMed ID: 7464063 [No Abstract] [Full Text] [Related]
6. Leprosy treatment and control of leprosy in India. (Assessment of achievements and suggestions for the future). Chatterjee SN Lepr India; 1980 Oct; 52(4):573-81. PubMed ID: 7193261 [No Abstract] [Full Text] [Related]
7. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy. Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592 [TBL] [Abstract][Full Text] [Related]
8. Elimination of leprosy: forecasts and projections. Gupte MD Indian J Lepr; 1994; 66(1):19-35. PubMed ID: 7983389 [No Abstract] [Full Text] [Related]
9. Chemotherapy of leprosy for control programmes. World Health Organ Tech Rep Ser; 1982; 675():1-33. PubMed ID: 6806990 [No Abstract] [Full Text] [Related]
10. Chemotherapeutic trials in leprosy. 2. Comparative trial of dapsone plus ditophal (Etisul) and dapsone alone in the treatment of lepromatous leprosy. Waters MF; Pettit JH Int J Lepr; 1965; 33(3):280-96. PubMed ID: 5322767 [No Abstract] [Full Text] [Related]
11. Kellersberger Memorial Lecture 1978. Leprosy control--present position and future prospects. Browne SG Ethiop Med J; 1978 Oct; 16(4):169-78. PubMed ID: 744197 [No Abstract] [Full Text] [Related]
12. Studies on risk of leprosy relapses in China: relapses after treatment with dapsone monotherapy. Chen XS; Li WZ; Jiang C; Ye GY Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):371-8. PubMed ID: 10700910 [TBL] [Abstract][Full Text] [Related]
13. Co-incident (simultaneous) dapsone sensitivity and dapsone-resistant leprosy. Pettit JH Int J Lepr Other Mycobact Dis; 1983 Jun; 51(2):258-9. PubMed ID: 6684650 [No Abstract] [Full Text] [Related]
14. Leprosy control in Shandong Province, China, 1955-1983; some epidemiological features. Li HY; Pan YL; Wang Y Int J Lepr Other Mycobact Dis; 1985 Mar; 53(1):79-85. PubMed ID: 3998564 [TBL] [Abstract][Full Text] [Related]
15. Dapsone resistant leprosy, the western Kenya experience. Orege PA; Owili DM Trop Geogr Med; 1985 Jun; 37(2):139-42. PubMed ID: 4035777 [TBL] [Abstract][Full Text] [Related]
16. Co-incident (simultaneous) dapsone sensitive and dapsone resistant leprosy. McDougall AC; Ross WF Int J Lepr Other Mycobact Dis; 1982 Jun; 50(2):214-5. PubMed ID: 6749709 [No Abstract] [Full Text] [Related]
17. Primary dapsone-resistant leprosy in Cebu, Philippines. Guinto RS; Cellona RV; Fajardo TT; de la Cruz EC Int J Lepr Other Mycobact Dis; 1981 Dec; 49(4):427-30. PubMed ID: 7042607 [TBL] [Abstract][Full Text] [Related]
18. Leprosy at a turning point? Harboe M Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):312-8. PubMed ID: 11221095 [No Abstract] [Full Text] [Related]
19. [Evaluation of leprosy mass screening campaign in Upper Volta after 10 years of activities (1966-1976)]. Blanc M Acta Leprol; 1978; (73):39-58. PubMed ID: 108912 [No Abstract] [Full Text] [Related]
20. Leprosy in children aged 0-14 years: report of an 11-year control programme. Keller R; Deen RD Lepr Rev; 1985 Sep; 56(3):239-48. PubMed ID: 4058234 [No Abstract] [Full Text] [Related] [Next] [New Search]